JP2022513320A5 - - Google Patents
Info
- Publication number
- JP2022513320A5 JP2022513320A5 JP2021542090A JP2021542090A JP2022513320A5 JP 2022513320 A5 JP2022513320 A5 JP 2022513320A5 JP 2021542090 A JP2021542090 A JP 2021542090A JP 2021542090 A JP2021542090 A JP 2021542090A JP 2022513320 A5 JP2022513320 A5 JP 2022513320A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- mutation
- flt3
- itd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024106255A JP2024114967A (ja) | 2018-10-01 | 2024-07-01 | Ｆｌｔ３が変異した血液のがんを処置する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739802P | 2018-10-01 | 2018-10-01 | |
| US62/739,802 | 2018-10-01 | ||
| US201962838239P | 2019-04-24 | 2019-04-24 | |
| US62/838,239 | 2019-04-24 | ||
| PCT/US2019/054142 WO2020072544A1 (en) | 2018-10-01 | 2019-10-01 | Methods of treating flt3-mutated hematologic cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024106255A Division JP2024114967A (ja) | 2018-10-01 | 2024-07-01 | Ｆｌｔ３が変異した血液のがんを処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513320A JP2022513320A (ja) | 2022-02-07 |
| JP2022513320A5 true JP2022513320A5 (https=) | 2022-10-12 |
Family
ID=70054475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542090A Pending JP2022513320A (ja) | 2018-10-01 | 2019-10-01 | Ｆｌｔ３が変異した血液のがんを処置する方法 |
| JP2024106255A Pending JP2024114967A (ja) | 2018-10-01 | 2024-07-01 | Ｆｌｔ３が変異した血液のがんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024106255A Pending JP2024114967A (ja) | 2018-10-01 | 2024-07-01 | Ｆｌｔ３が変異した血液のがんを処置する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220008448A1 (https=) |
| EP (1) | EP3860655A4 (https=) |
| JP (2) | JP2022513320A (https=) |
| WO (1) | WO2020072544A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113502332B (zh) * | 2021-09-07 | 2021-12-17 | 广东永诺医疗科技有限公司 | 一种用于检测flt3基因突变的引物、探针及试剂盒 |
| US20250049787A1 (en) * | 2021-12-22 | 2025-02-13 | University Health Network | Treatment for acute myeloid leukemia or lymphoma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10517876B2 (en) * | 2005-11-16 | 2019-12-31 | Cti Biopharma Corp. | Oxygen linked pyrimidine derivatives |
| WO2007058627A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Oxygen linked pyrimidine derivatives |
| ES2811804T3 (es) * | 2013-10-31 | 2021-03-15 | Biokine Therapeutics Ltd | Un inhibidor peptídico de CXCR4 para su uso en el tratamiento de la leucemia mieloide aguda con una mutación de FLT3 |
-
2019
- 2019-10-01 WO PCT/US2019/054142 patent/WO2020072544A1/en not_active Ceased
- 2019-10-01 EP EP19869352.5A patent/EP3860655A4/en active Pending
- 2019-10-01 JP JP2021542090A patent/JP2022513320A/ja active Pending
- 2019-10-01 US US17/282,170 patent/US20220008448A1/en not_active Abandoned
-
2024
- 2024-07-01 JP JP2024106255A patent/JP2024114967A/ja active Pending
- 2024-11-21 US US18/954,998 patent/US20250319111A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233563A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations | |
| Kim et al. | Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor | |
| JP6769962B2 (ja) | 癌治療のためのキナーゼ阻害剤プロドラッグ | |
| ES2742310T3 (es) | Método y kit para la detección no invasiva de mutaciones del gen EGFR | |
| TWI893039B (zh) | 透過循環腫瘤dna分析之分子疾病評估之方法及系統 | |
| JP7778753B2 (ja) | テロメラーゼ阻害剤による治療から利益を得る可能性が高い患者を特定する方法 | |
| JP2022527788A5 (https=) | ||
| US20220175779A1 (en) | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations | |
| CN110741096B (zh) | 用于检测循环肿瘤dna的组合物和方法 | |
| US11814688B2 (en) | Markers for determining tumor hypoxia | |
| JP2022513320A5 (https=) | ||
| WO2012041332A2 (en) | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors | |
| CA2972076A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| EP3773551B1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| Widasari et al. | A deep-sequencing method detects drug-resistant mutations in the hepatitis B virus in Indonesians | |
| WO2021028768A1 (en) | METHOD FOR ALTERING THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS BASED ON ANALYSIS OF ctDNA | |
| US20200316067A1 (en) | Combination of raf inhibitors and taxanes | |
| WO2025246530A1 (en) | Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting | |
| US20240041998A1 (en) | Methods and compositions for sensitizing prc2 mutant tumors to immune checkpoint blockade therapy | |
| Sathiyamoorthy et al. | Study on PIK3CA gene mutations in oral squamous cell carcinoma among South Indian populations | |
| US20240219403A1 (en) | Methods for inhibiting kras oncoprotein through enhanced gtpase activity | |
| US20250101522A1 (en) | Brca1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy | |
| US20260043078A1 (en) | Sequencing methods with partitioning | |
| WO2025128887A1 (en) | Methods and compositions for selective enrichment of methylation signal | |
| Yassin et al. | Internal tandem duplication of FLT3 gene in Egyptian pediatric acute myeloid leukemia and acute lymphoblastic leukemia |